News archive

Eighteen kidney researchers at Karolinska Institutet have been allocated grants totaling 3.2 million Swedish kronor from the Swedish Kidney Foundation, an announcement made in connection with World Kidney Day on March 9.

The new president of Karolinska Institutet, Annika Östman Wernerson, is professor of renal and transplantation science and has a passion for pedagogical research. Internal culture and building ‘one KI’ by strengthening the dialogue and communication between management, departments, staff and students is one of her biggest driving forces.

Researchers from the Department of Neurobiology, Care Sciences and Society (Eriksdotter group) in collaboration with the Departments of MEB (Carrero group) and Clintec (Bruchfeld group) at KI have recently had their study published in Kidney International (IF 19). This paper is the first study linking activation of cholinergic anti-inflammatory pathways to kidney damage in humans.

Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumour spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet in a preclinical study published in Nature Communications.

Women with reduced kidney function received a diagnosis of chronic kidney disease to a less extent than men in the same situation. Women were also less likely to have their kidney function monitored, to visit a nephrologist and to use recommended treatments for chronic kidney disease. This according to a new study by researchers from Karolinska Institutet published in the Journal of the American Society of Nephrology.

Researchers at Karolinska Institutet have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell. When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment. Their findings, which are published in Nature Metabolism, offer hope for more targeted cancer drugs.

The Swedish Kidney Foundation has appointed the researchers who will be receiving money this year for kidney research. Out of a total of 49 researchers and SEK 6.1 million, 19 researchers at Karolinska Institutet will share SEK 2.2 million. In connection with the recognition of the grants, one KI researcher will be awarded the Bengt Rippes Research Prize.

Older people with kidney disease have a higher risk of dementia, and the risk increases with the rate and stage of kidney function decline. That is according to a large observational study by researchers at Karolinska Institutet, published in the journal Neurology. The findings stress the significance of screening and monitoring for dementia in persons with kidney disease, the researchers say.

The European Renal Association – European Dialysis and Transplant Association has just announced their annual awards and Professor Juan-Jesus Carrero from the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet will receive the ERA-EDTA Award for Research Excellence for his work in kidney epidemiology, on June 7, 2021 at the 58th ERA-EDTA Congress.

Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients. Researchers at Karolinska Institutet now show that although stopping the treatment is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events and death. The results are published in The Journal of the American Society of Nephrology.

Active lifestyle choices such as eating vegetables, exercising and quitting smoking can reduce the risk of chronic kidney disease, a new study led by researchers at Karolinska Institutet in Sweden and Griffith University in Australia, reports. The study is published in the Journal of the American Society of Nephrology.

Use of sodium glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes may help to lower the risk of serious kidney problems, according to a Scandinavian study led by researchers at Karolinska Institutet. The findings, now published in the journal The BMJ, provide support for the use of SGLT2 inhibitors in a broad range of patients with type 2 diabetes, according to the researchers.

Rates of people dying from chronic kidney disease are expected to increase in the coming years unless more countries invest in preventative measures and early treatment. That is the conclusion of a global systematic analysis by the international research consortium Global Burden of Disease, published today in the scientific journal The Lancet. The study was led in part by Professor Johan Ärnlöv at Karolinska Institutet in Sweden.